Skip to content Skip to footer
Subscribe Now

INSIGHTS+

PharmaShots' Key Highlights of Third Quarter 2019
PharmaShots’ Key Highlights of Third Quarter 2019
The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer's Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired…
September 7, 2019
Insights+ Key Biosimilars Events of July 2019
Insights+ Key Biosimilars Events of July 2019
Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars 'a reference product to biologics' which are biologically like biologics. They possess similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots have…
August 10, 2019
PharmaShots' Key Highlights of First Quarter 2019
PharmaShots’ Key Highlights of First Quarter 2019
The first quarter of 2019 has marked with major events in the pharma & biotech industries. We have gathered the key highlights of the quarter, which was starting with the blockbuster news, where Celgene had acquired BMS for $74B. Moving to the next news, acquisition of Loxo Oncology for $8B, in addition to Spark Therapeutics’…
August 4, 2019
Insights+: Key Events of ASCO 2019
Insights+: Key Events of ASCO 2019
The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on latest advancement and new approaches in cancer research. In the 55th session of ASCO 2019, 2400+ abstracts were presented. IBM Watson Health was also a part of ASCO 2019 with its advancement in Oncology, Genomics and Patient Monitoring.…
July 6, 2019
Insights+ Key Biosimilars Events of June 2019
Insights+ Key Biosimilars Events of June 2019
Biosimilars are key alternatives for costly Biologics therapies and saving million dollars of patients in multiple diseases. Hence physicians are likely to adopt biosimilars a reference product to biologics which are biologically like biologics. They possess similar therapeutic properties in terms of potency, safety, and efficacy to original biologic products. Our team at PharmaShots have…
July 4, 2019
PharmaShots' Key Highlights of Second Quarter 2019
PharmaShots’ Key Highlights of Second Quarter 2019
The second quarter of 2019 has ended with major acquisitions in pharma and biotech industry. Moving with the latest acquisition of Allergan for $63B by AbbVie focusing on to generate revenue with addition of Allergan's medical aesthetics and ophthalmology portfolio. Prior to that, Pfizer acquired Array Biopharma for $11.4B to expand its oncology portfolio. Some…
July 3, 2019
Insights+ Key Biosimilars Events of May 2019
Insights+ Key Biosimilars Events of May 2019
Biosimilars are going in market with vast emerging needs of people for multiple diseases. The biologics that are too costly to be used in the markets. Hence physicians are developing biosimilars a reference product to biologics which are biologically similar to biologics. Our team at PharmaShots have summarized some of the news regarding biosimilars in…
June 4, 2019
Insights+: Breakthrough Therapy Designation by the US FDA in 2018
Insights+: Breakthrough Therapy Designation by the US FDA in 2018
Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012. The Breakthrough Designation is granted to the drugs as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available therapies…
May 8, 2019
Insights+: The US FDA New Drug Approvals in 2018
Insights+: The US FDA New Drug Approvals in 2018
1. Janssen's Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Published: 14 Feb,2018 | Tags: Janssen, Erleada, apalutamide, Receives, FDA, Approval, Non-Metastatic Castration-Resistant Prostate Cancer, NM-CRPC 2. Helsinn's (fosnetupitant + palonosetron) Receives FDA Approval for Managing Chemotherapy-Induced Nausea and Vomiting (CINV) Published: 14 Feb,2018 | Tags: Helsins, fosnetupitant + palonosetron, Receives, FDA, Approval, Managing Chemotherapy-Induced Nausea and Vomiting,…
March 4, 2019
Load more